Despite over half a century of progress in protein detection technologies, much of the human plasma proteome remains invisible and inaccessible to current technologies.
Addressing this long-standing challenge requires developing a technology that can interrogate the proteome deeply with ultra-high sensitivity to detect very low abundance proteins, and broadly with the ability to measure hundreds to thousands of proteins in parallel in a single sample in a high-throughput manner.
The current state-of-the-art methods of proteomic analysis all make tradeoffs sacrificing either depth or breadth.
NUCLEIC ACID-LINKED IMMUNO-SANDWICH ASSAY
NULISA™ Our NUcleic acid-Linked Immuno-Sandwich Assay platform reinvents the immunoassay by leveraging our proprietary signal-to-noise ratio enhancement technology and the latest advances in Next-Gen Sequencing (NGS) to provide both ultra-high sensitivity and massively parallel scale to proteomic analysis.
"Real-world assay sensitivity requires more than just single molecule detection."
ANTIBODY ENGINEERING
Attobody™ Our novel antibody engineering platform consists of a proprietary design framework and an efficient discovery process that yields picomolar affinity antibodies with built-in high specificity.
By combining NULISA and Attobody together, our platform can achieve single-digit attomolar detection limit, greatly surpassing the most sensitive protein detection technology on the market today. This lays a new foundation for precision proteomics with the potential to transform healthcare.
Uncover new biomarkers
The unprecedented sensitivity and high multiplexing will uncover powerful new biomarkers that are hidden today and enable a new generation of precision diagnostics for the early detection of cancer and other common diseases. Eventually, this technology could lead to prevention of these diseases through comprehensive health monitoring.
Enable novel Immunotherapies
The high affinity and specificity of Attobodies can be leveraged to develop highly selective and efficacious targeted therapeutics. This expands antibody therapeutics to many intractable targets such GPCRs and ion channels as well as enabling novel immunotherapies.
Alamar Biosciences, Inc.
47071 Bayside Pkwy
Fremont, CA 94538
1 (510) 626-9888
Fax: (510) 605-5062